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In recent years, rapid advances were reached in the understanding of a series of biologic signals influencing cutaneous malignant
melanoma (CMM) cells. CMM is in close contact with a peculiar dermal extracellular matrix (ECM). Stromal cells store and release
various structural ECM components. The impact on CMM growth and progression is mediated through strong and long-lasting
eﬀects of ECM products. This paper summarizes some peculiar aspects of the peri-CMM stroma showing intracytoplasmic loads
in Factor XIIIa, CD34, versican, and α (IV) collagen chains. The restricted peri-CMM skin territory exhibiting such changes
corresponds to the area showing neoangiogenesis and extravascular unicellular metastatic spread. The latter inconspicuous
migratory CMM cells possibly correspond to CMM stem cells or to CMM cells with aberrant HOX gene expression. Their
presence is associated with an increased risk for metastases in the regional sentinel lymph nodes. In conclusion, the CMM-stroma
connection appears crucial to the growth regulation, invasiveness and initial metastatic spread of CMM cells. Although much
remains to be learned in this field, the active intervention of the peri-CMM stroma is likely involved in the inconspicuous early
metastatic migration of CMM cells.
1. Introduction
Human cutaneous malignant melanoma (CMM) basically
corresponds to an uncontrolled overgrowth of neoplas-
tic melanocytes. However, the extracellular matrix (ECM)
and the connective tissue cells adjacent to the neoplasm
probably represent more than passive bystanders in CMM.
The biology and prognostic significance of some tumoral
components are increasingly established [1, 2], but the
relationship between CMMcells and the nonimmune aspects
of the peritumoral stroma remains poorly understood. The
CMM-stroma cross-talk is regulated by soluble factors and
by direct cell-cell contact [3]. It is a commonplace to suggest
that CMMs with little fibroblasts are quite aggressive, but
this assumption is not firmly rooted in evidence-based
observations. The influence onmetastatic spread is unsettled.
The aim of this paper is to summarize the evidence on the
changes in the nature of stromal cells and their products in
the peri-CMM stroma during tumor invasion and metastatic
dissemination.
2. Pathobiology of Regular and
Desmoplastic Melanomas
At a key point in tumor progression, CMM starts to express
a high metastatic potential before causing mortality. In order
to form distant metastases, malignant cells have to acquire
specific functions and properties in an orderly sequence
[4]. In particular, some interactions exist between CMM
cells and various biologic systems including environmental
factors, immune cells, vascularity, contiguous stromal cells,
and molecular components of the dermal ECM [5–7].
Some aspects of the CMM-stroma interactions including
the release of growth factors and matrix metalloproteinases
(MMP) are likely associated with the disease progression and
prognosis [7–11].
Cell functions required in the CMM metastatic cascade
are not limited to intrinsic properties of the neoplastic
cells. Many properties are regulated or influenced by the
close microenvironment [12, 13]. In addition, neoplastic
cells are able to induce changes in the surrounding tissues
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[14, 15]. Thus, CMM cells and their surrounding stroma
jointly form a specific and complex microecosystem [10,
16]. Cross-talk between CMM and stromal cells is likely
mediated through a combination of direct heterotypic cell-
cell contacts, adhesion molecules, signaling factors, as well as
other secretedmolecules including growth factors, cytokines,
chemokines, ECM proteins, MMPs, proteinase inhibitors,
and lipids [3, 17]. Conceptually, the CMM microecosystem
is crucial for the maintenance of both the cell functions and
tissue integrity suggesting that any CMM-induced change
in the stroma contributes to the neoplastic progression and
invasiveness [18]. Any alteration in the CMM stroma is
likely related to various imbalances in the cytokine profile,
resulting from the oncogenic changes in the neoplastic cells.
In particular, experimental animalmodels demonstrated that
cancer invasion was stimulated by the wound-healing stroma
[19].
Both stromal cells and ECM components located beneath
primary CMM are therefore involved in both the neoplastic
invasive process and the early dissemination of micrometas-
tases associated or not with neoangiogenesis [2, 20–23].
These characteristics are expected to be related to phenotypic
changes in the stromal cells in the CMM vicinity [10].
The three-dimensional relationship between neoplastic
cells and stroma varies among tumors. In benign tumors, a
clear cut separation exists between neoplastic cells and the
connective tissue. By contrast, especially in malignancies,
areas of tumoral cells and stroma are merging, since the
former ones often invade the latter structures.
Desmoplastic melanoma is a rare and specific cyto-
morphologic variant in the CMM spectrum [24]. This
neoplasm exhibits a clinical behavior distinct from reg-
ular CMM, including frequent local recurrences. The
neoplastic melanocytes commonly exhibit unusual poorly
diﬀerentiated phenotypic characteristics. Microscopic fea-
tures of desmoplastic melanoma are distinct from reg-
ular CMM. They consist of invasive neoplastic spindle-
shaped melanocytes encased in a striking desmoplastic
stroma. Fibroblast-like cells are intimately admixed with
the neoplastic melanocytes. They exhibit either a single-
cell dispersal pattern within the sclerotic dermis or are
disposed in long fascicles. Desmoplasia is commonly related
to a variety of cell lines including numerous Factor XIIIa+
dermal dendrocytes (DDs) and rare α-actin+ myofibroblasts
(MFs). In addition, CD45+ lymphocytes and Mac 387+
monocytes/macrophages are clustered inside desmoplastic
melanoma.
3. Tumor Cell Involvement inMicrometastases
The primary CMM thickness impacts the prognosis of
the neoplasia. Primary CMMs less than 1mm thick are
associated with high cure rate and unaﬀected survival.
This situation sharply contrasts with the poor prognosis of
thicker CMM. The apparent breakpoint beyond about 1mm
thickness is a dramatic aspect for the disease outcome. One
possible reason appears to be linked to the CMM vascu-
larization patterns [25–28]. Such microanatomic feature is
persuasive, but it is by no means the single one [25].
The concept of dormant CMM metastases [29] was
oﬀered to explain (a) why some CMMs develop metastases
after disease-free intervals as long as 10–40 years following
excision of the primary CMM, (b) the therapeutic failure of
wide surgical resection margins, and (c) the vain hope placed
in elective lymph node dissection to influence prognosis.
Once CMM metastases have developed, the subsequent
prognosis is fairly predictable, irrespective of the preced-
ing disease-free interval. These observations suggest that
microscopic CMM foci likely remain quiescent in their own
microenvironment for variable periods of time before some
event(s) trigger(s) the development of detectable/progressive
metastases.
The metastatic potential is expressed by variant subpop-
ulations of metastatically competent CMM cells present in
the primary neoplasms [2]. These subpopulations typically
exhibit over time a growth advantage at the primary site
leading to a dominant proliferating population [2]. At this
stage, CMMs express overt malignancy and clonal domi-
nance of metastatically competent cells. Most thin primary
CMMs only contain few, if any, metastatically competent
cells, whereas thicker CMMs contain increased proportions
of such cells. The stromal microecosystem is in part involved
in such a shift in the biologic profile [30].
3.1. Melanoma Stem/Progenitor Cells. The presence of CMM
stem cells is in part involved in the process of CMM
micrometastases and in their relationship with the peritu-
moral stroma [20, 31–36]. CMM stem cells are capable of
indefinite self-renewal, a function linked to CMM growth
[2, 34, 37]. Although conventional anticancer treatments
aim at eradicating malignant cells, they are potentially inef-
fective against chemoresistant cancer stem cells, which are
ultimately responsible for neoplastic recurrence, progression,
and metastasis [2, 20, 31].
CMM typically exhibits cell heterogeneity, undiﬀeren-
tiated molecular signatures, and increased tumorigenicity
restricted to specific CMM subsets with embryonic-like
diﬀerentiation plasticity. These features strongly suggest
the involvement of CMM stem cells in the initiation and
spreading of this malignancy [31–33, 35, 38–41]. Both the
structure and biologic specificity of the ECM are potentially
involved in the invasiveness and propagation of CMM stem
cells.
3.2. The Metastatic Paths. The generation of CMM metas-
tases at distant sites relies on adequate genotypic and
phenotypic characteristics acquired in an orderly sequence
referred to as the CMM metastatic cascade. Such a process
encompasses boosted CMM cell proliferation, detachment
from the primary neoplasm, interaction with and invasion
into the peritumoral stroma, penetration into blood and
lymphatic vessels, survival in the circulation, adhesion to a
vessel wall at the final metastatic site, extravasation, survival
in the new ECM, and proliferation to form overt metastasis
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[2, 5]. Thus, basically, the specific functions involved in
the metastatic cascade combine intrinsic characteristics of
some CMM cells and the regulatory influences from the
microenvironment. Indeed, CMM cells and their surround-
ing stroma jointly form a microecosystem receptive to early
inconspicuous metastatic spread [8].
The early CMM micrometastases are poorly discernable
at the regular clinical or dermoscopic examinations. By
contrast, most of them are disclosed under the microscope,
particularly with the help of immunohistochemistry [2, 10,
22, 42]. They are found in four main distinct locations,
namely, (a) inside lymph vessels, (b) inside blood vessels, (c)
in a perivascular location just abutted to the outer aspect of
the endothelial lining, and (d) dispersed inside the stroma
[20, 21, 23]. The latter eventuality is frequently associated
with neoangiogenesis, and a boosted neoplastic germinative
pool is commonly found [20, 28].
The active migration of metastatic CMM cells in the
peritumoral stroma is probably a complex process. It involves
both the active migration of CMM cells and changes in the
CMM cell adherence systems with ECM components. Neo-
plastic thigmotropism is in part involved in the migration
path [43].
Interstitial unicellular or paucicellular CMM
micrometastases are occasionally found and confined
to the perineoplastic stroma. Their presence is statistically
correlated with the risk of invasion of the sentinel lymph
node [22]. Microarray studies have identified some
transcriptional diﬀerences during the metastatic cascade [4].
Of note, overexpression of some homeobox (HOX) genes
is typically present in CMM cells susceptible to generate
metastases. This facet of CMM pathobiology conveniently
revealed using immunohistochemistry shows correlation
with specific changes in the peritumoral stroma as described
hereafter. The role of homeobox (HOX) gene overexpression
has been highlighted in the evolving process of CMM
metastasis [44–47]. In addition, the MMP expression is
altered. Although MMPs are typically degradative enzymes
with the ability to cleave ECM proteins such as collagen and
fibronectin, their dominant role is actually a signal-altering
eﬀector [48]. These nonmatrix-degrading functions of
MMPs vastly expand the ways in which they contribute to
various pathologies, including CMM progression.
4. Stroma Immunohistochemistry Abutted
toMalignant Melanoma
At the regular histopathology examination, stromal cells look
normal underneath primary CMM when partial regression
is not obvious. However, their diﬀerentiation as revealed by
immunohistochemistry appeared altered when compared to
the surrounding skin. In particular, phenotypic changes were
found in the expression of the transglutaminase Factor XIIIa,
CD34, the α (IV) collagen chains, the α- and β-actins, as well
as elafin and versican. It is possible although not yet proven
that transforming growth factor-β1 (TGF-β) and platelet-
derived growth factor (PDGF) play a role in changing the
stromal host compartment in CMM.
4.1. Factor XIIIa-Enriched Stromal Cells. Factor XIII exerts
a major function in the area of hemostasis. It has a hetero-
tetrameric structure which consists of two globular A units
and two strandlike B subunits. The A subunit is a proen-
zyme circulating in the blood and present intracellularly in
platelets and monocyte-macrophages.
Factor XIIIa-enriched stromal cells of the skin are com-
monly identified as DDs type I. The intracytoplasmic subunit
A is a specific transglutaminase [49]. The cells belong to
the monocyte-macrophage lineages preferentially abutted to
the superficial microvasculature [50–52]. Increased numbers
of Factor XIIIa+ DD are often found in the vicinity of
most invasive cutaneous neoplasms. They are particularly
numerous, abutted to and infiltrating most thin CMM [30].
By contrast, they are fewer or even absent in thick primary
CMM and their metastases [52–55]. Circumstantial evidence
correlated the density of Factor XIIIa+ DD and a low
proliferative rate of CMM cells [30]. Thus, Factor XIIIa+ DD
are probably not passive bystanders in CMM [29, 48, 49].
Their function possibly diﬀers based on whether they are
located in the stroma or inside the neoplasm. Intratumoral
DD appeared associated with a growth-restricting role.
In contrast, stromal DDs contribute to the invasiveness
and metastatic spread of CMM cells. This role in CMM
invasiveness is putative but it unambiguously opens new lines
of inquiry about the biologic functions of Factor XIIIa.
4.2. CD34-Positive Stromal Cells. CD34+ type II DDs are
constitutive cells of the dermal stroma. Invasive CMMs are
frequently associated with a decrease in these cells [56].
4.3. Collagen-IV-Enriched Stromal Cells. In malignant neo-
plasms, basement membranes (BMs) are composite struc-
tures synthesized by tumoral cells, stromal cells, by one of
these two cell types, but depending on interactions between
them, or are a mixture from both origins. These tumor-
associated BMs are often abnormal in their composition and
ultrastructure [57, 58]. BM material seems rather accom-
panying malignant cells rather than preventing invasion as
a physical barrier. Nevertheless, active interactions between
neoplastic cells and stroma, in particular the ECM, play a
key role in the neoplastic progression leading to invasion
and metastasis [59]. Several BM components were identified
around CMM cells including collagen IV [57, 60–62]. In the
skin, collagen IV represents an assembly of α1 (IV) and α5
(IV) collagen chains. In CMM, some neoplastic cells and
stromal cells exhibit intracytoplasmic immunolabeling for
α1 (IV) chains [62]. The pattern is heterogeneous, and BM
components including type IV collagen gradually disappear
during the dermal ingrowth of CMM cells. Of note, a
minority of CMM without any identifiable micrometastasis
and a majority of CMMs with cutaneous micrometastasis
show discrete cytoplasmic positivity for the α5 (IV) collagen
chain [60].
The distribution of α1 (IV) collagen chain in CMM
highlights the heterogeneity in both cell diﬀerentiation and
stroma-CMM interactions. Thus, CMM cells appear to have
their own individual potential to be wrapped by a BM and
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to interact with the stroma. This biologic aspect is likely
related to the neoplastic progression and it influences the
inconspicuous metastatic potential.
4.4. Versican-Enriched Stromal Cells. Versican is a large
proteoglycan normally present inside stromal cells of the
skin. The molecule belongs to the chondroitin sulfate family
of the hyalectan group, named from its ability to bind to
hyaluronan [63]. In mammals, versican appears as four
possible spliced isoforms named V0 to V3. Little is known
about the diﬀerential regulation of the isoforms and about
their respective roles in the ECM either normal or peri-
tumoral. The versican production is deregulated in several
human cancers [64]. As it is largely expressed in fast-growing
neoplastic cells, it has been suggested to play a direct role in
cell proliferation and other cell functions [63]. It appeared
to be particularly abundant in the stromal cell population
underneath CMM [64–71]. The overexpression was sharply
circumscribed to a cup-shape structure cuﬃng the bottom
of CMM. In addition, some nests of CMM cells were strongly
labeled with the antiversican antibody. Such finding contrasts
with another study having reported the absence of versican
immunoreactivity in neoplastic melanocytes [67]. Versican
expression did not correlate with Breslow tumor thickness
and Clark’s level [67].
4.5. Protomyofibroblasts andMyofibroblasts. The peritumoral
stroma of some CMMs contains both MF and their
precursors, the protomyofibroblasts. Any MF resembles a
peculiar fibroblast-like cell, exhibiting features of a smooth
muscle (SM) cell, including microfilament bundles, with
interspersed dense bodies, and intercellular gap junctions.
MFs are present in most fibrotic conditions. The MF struc-
ture is characterized by stress fibres formed by contractile
proteins, particularly α-SM actin (α-SMA). MFs originate
from protomyofibroblasts whose stress fibers contain β- and
γ-actins. They possibly evolve to regular MFs enriched in α-
SMA [72].
The switch from the protomyofibroblast to mature
MF probably results from the production and release of
transforming growth factor-β1 (TGF-β1) by inflammatory
and fibroblast-like cells. The TGF-β1 action is mediated by
the cellular fibronectin splice variant ED-A [72]. Thus, MF
diﬀerentiation is regulated by both specific cell components
and some ECM molecules. Endothelin-1, thrombin, and
mechanobiology promote MF induction [73, 74].
Contrasting with melanocytic nevi and desmoplastic
melanomas, the stroma of most regular CMM appears to be
devoid in MF exhibiting α-SMA immunoreactivity [56, 75].
β-SMA+ protomyofibroblasts are rare as well.
4.6. Elafin-, Versican-, and Lysozyme-Loaded ECM. Elastic
fibres are coated by distinct molecules following chronic
ultraviolet light exposures [76–78]. The serine antileuko-
protease elafin, and versican and lysozyme as well bind to
elastin preventing elastolytic degradation by elastases on
sun-exposed areas exhibiting solar elastosis [77–79]. Elastase
inhibition possibly decreases the adhesion of cancer cells to
endothelial cells [80].
In addition, elafin was reported to elicit p53-dependent
apoptosis in cultured CMM cells transfected by a plasmid
producing elafin under doxycycline boosting [81]. Contrast-
ing with such in vitro experiments, immunohistochemistry
did not disclose intratumoral cell presence of elafin in human
CMM. Rather, keratinocytes covering CMM overexpressed
elafin in their cytoplasm. Of note, Western blot and reverse
transcription analyses indicated transcriptional elafin repres-
sion in CMM cells [81].
5. Tumors: Wounds That Do Not Heal?
About 25 years ago, the comparison of tumors and wounds
led to an intriguing concept considering the resemblance
between cancers and wounds [82]. The comparison was
based on molecular and biologic features occurring in
wound healing on the one hand and in neoplasms on the
other hand. If most observations indicate that many neo-
plastic cells induce stroma formation, the reverse question
explored the possible induction of tumor cell development
by a scar. The involvement of fibroblasts in CMM stromage-
nesis occurs through diﬀerent stages involving their recruit-
ment, activation, and conversion to MF, or diﬀerentiation to
fibrocytes. Such involvement is topographically linked to dif-
ferent areas inside and around CMM, and stromal activation,
as seen in tumor ulceration and immunologically-driven
regression of CMM stimulating neoplastic progression [3].
6. Discussion
In general, the peritumoral stroma creates a kind of scaﬀold-
ing for the neoplasm. In particular, a singular ECM structure
is abutted to the deep part of primary CMM. Stromal
cells exhibit particular phenotypic aspects suggesting altered
functionality. The involved territory seems conductive to
a micrometastatic spread. Some of these metastatic cells
survive singly and are possibly in their way of migration to
other organs. They possibly correspond to CMM stem cells
or to mature CMM cells with HOX gene dysfunctions.
The intimate relationship between neoplastic cells and
their stroma is a fascinating topic orienting the translational
research in therapy. Beyond the importance of CMM vascu-
larity for the tumoral growth, invasiveness, and metastatic
spread [20–26, 83, 84], a series of other roles are ascribed to
the tumoral stroma. Such a structure is involved in a constant
remodelling following degradation and repair of the ECM. In
addition, some environmental influences including ultravi-
olet light exposures are involved in the CMM initiation. In
addition, they support the neoplastic progression through
the intervention of diverse autocrine and paracrine factors
[85]. Of note, immunohistochemistry highlights the direct
implication of CMM cells in the synthesis and/or storage of
some ECMmolecular components.
The immunohistochemistry characterization of CMM
cells is informative [8, 34, 86–91], but it should probably be
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extended to its peritumoral stroma including the microvas-
culature [20, 25, 26, 83], the stromal cells, and ECM compo-
nents as well. A comprehensive mapping of CMM genotypic
and phenotypic characteristics identifies relevant targeted
therapies [89, 91–99]. Inflammatory cells and immunocytes
represent another class of host cells that are regulated by
cytokine balances. They perform countercurrent invasion,
from the circulation into the neoplasm, and provide roads
for CMM cell invasion. The global host involvement in the
cancer microecosystem basically relies on the microvascu-
lature, the stromal cells and the specific immune reactions
[10, 20, 100]. Angiogenesis is a host-mediated response to
many cancers. It appears crucial for cancer progression, as
blood vessels deliver nutrients and oxygen to the neoplas-
tic cells [25]. Furthermore, the microvasculature possibly
allows communication between the primary CMM and its
metastases. Proangiogenic molecules originate from both
cancer cells and the stromal microenvironment. The relative
contribution of both compartments is likely to be influenced
by the CMM type and site and is balanced by other factors as
well [25, 26].
7. Conclusion
The multiple interactions between CMM and its stroma
are beyond doubt, in particular during the invasive and
metastatic phases of evolution. Stromal cells are recognized
to secrete metalloproteinases and their inhibitors, growth
factors, and other soluble mediators as well participating
in the growth and mobility of the CMM cells. In addition,
some other molecules are synthesized and overexpressed
by stromal cells and/or CMM cells. Immunohistochemistry
conveniently identifies Factor XIII-a, α1 and α5 (IV) col-
lagen chains, versican, elafin, and lysozyme. They possibly
influence the migration and thigmotropism of CMM cells
including their stem cells.
While CMM cell motility cannot be directly assessed,
there is circumstantial evidence that mobility is operative
in CMM progression and possibly indicative for prognostic
purposes. In addition to the secretion and activation of
enzymes modeling the ECM, a variety of stromal changes
occur following overexpression of diverse ECM components.
Molecular morphology yields evidence suggesting that the
CMM stroma plays an integral role in the neoplastic evo-
lution. Although much remains to be learned, the presently
summarized changes have diagnostic and prognostic signifi-
cance that merit to be scrutinized in future works.
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